Sinovac Biotech Ltd., of Beijing, said the CFDA issued the good manufacturing practices certificate for the company's enterovirus 71 vaccine, marking the final step of approval prior to commercial production. Sinovac expects to deliver the vaccine to the market prior to the end of the second quarter. The designed annual production capacity is 20 million doses. Enterovirus 71 is the virus that causes hand, foot and mouth disease.